Read by QxMD icon Read

Ovarian cancer treatment summary

Katerina Vavrova, Petra Vrabcova, Dominik Filipp, Jirina Bartunkova, Rudolf Horvath
Adoptive T cell transfer has been shown to be an effective method used to boost tumor-specific immune responses in several types of malignancies. In this study, we set out to optimize the ACT protocol for the experimental treatment of prostate cancer. The protocol includes a pre-stimulation step whereby T cells were primed with autologous dendritic cells loaded with the high hydrostatic pressure-treated prostate cancer cell line, LNCaP. Primed T cells were further expanded in vitro with anti-CD3/CD28 Dynabeads in the WAVE bioreactor 2/10 system and tested for cytotoxicity...
December 2016: Medical Oncology
Si Sun, Jing Cai, Qiang Yang, Yapei Zhu, Simei Zhao, Zehua Wang
BACKGROUND: Chemotherapy resistance is reported to correlate with up-regulation of anti-tumor agent transporter ABCB1 (p-gp) in epithelial ovarian cancer (EOC), but the results remain controversial. To reconcile the results, a systematic review followed by meta-analysis was performed to assess the association between high ABCB1 status or ABCB1 gene variants and overall survival (OS), progression free survival (PFS), and total response rate (TR) in patients with EOC. MATERIALS AND METHODS: Electronic searches were performed using Pubmed, EMBASE, Web of Science and Chinese Wanfang databases from January 1990 to February 2016...
2016: PloS One
Shibing Wang, Jing Shu, Li Chen, Xiaopan Chen, Jianhong Zhao, Shuangshuang Li, Xiaozhou Mou, Xiangmin Tong
Gene therapy on the basis of oncolytic adenovirus is a novel approach for human cancer therapeutics. We aim to investigate whether it will synergistically reinforce their antiovarian cancer activities when the combined use of ZD55-manganese superoxide dismutase (MnSOD) and cisplatin was performed. The experiments in vitro showed that ZD55-MnSOD enhances cisplatin-induced apoptosis and causes remarkable ovarian cancer cell death. Apoptosis induction by treatment with ZD55-MnSOD and/or cisplatin was detected in SKOV-3 by apoptotic cell staining, flow cytometry, and western blot analysis...
2016: OncoTargets and Therapy
Defeng Kuang, Xiaoping Zhang, Shaofang Hua, Wei Dong, Zhiguo Li
Ovarian cancer is the fifth leading cause of cancer-related death in women worldwide, and recent studies have highlighted the role of long non-coding RNAs (lncRNAs) in cancer development. However, the role of lncRNAs in ovarian cancer is largely unclear. In this study, we focused on the taurine up-regulated gene 1 (TUG1) and examined its molecular mechanism in ovarian cancer. Here, we reported that TUG1 was up-regulated in ovarian cancer tissues and ovarian cancer cells, and TUG1 expression was positively correlated with tumor grade and FIGO stage...
September 28, 2016: Experimental and Molecular Pathology
Y Fujii, T Fujiwara, Y Koide, I Hasan, S Sugawara, S Rajia, S M A Kawsar, D Yamamoto, D Araki, R A Kanaly, Y Ogawa, H Fujita, Y Ozeki
An N-acetyl sugar-binding lectin (termed iNoL) displaying cytotoxic activity against human cancer cells was isolated from the slipper lobster Ibacus novemdentatus (family Scyllaridae). iNoL recognized monosaccharides containing N-acetyl group, and glycoproteins (e.g., BSM) containing oligosaccharides with N-acetyl sugar. iNoL was composed of five subunits (330, 260, 200, 140, and 30 kDa), which in turn consisted of 70-, 40-, and 30-kDa polypeptides held together by disulfide bonds. Electron microscopic observations and gel permeation chromatography indicated that iNoL was a huge (500-kDa) molecule and had a polygonal structure under physiological conditions...
September 22, 2016: Glycoconjugate Journal
Beth Y Karlan, Ronald D Alvarez, Jerome F Strauss
The National Academies of Sciences, Engineering, and Medicine convened an expert committee to examine and summarize the state of the science in ovarian cancer research. An Executive Summary of the recently released report describing the key findings and specific recommendations to reduce the incidence of and morbidity and mortality from ovarian cancers is presented. Highlights include the recognition that ovarian cancer is not just one disease, but rather a constellation of distinct cancer types, some of which originate outside of the ovary...
October 2016: Obstetrics and Gynecology
Dolores Gallardo-Rincón, Raquel Espinosa-Romero, Wendy Rosemary Muñoz, Roberto Mendoza-Martínez, Susana Del Villar-Álvarez, Luis Oñate-Ocaña, David Isla-Ortiz, Juan Pablo Márquez-Manríquez, Ángel Apodaca-Cruz, Abelardo Meneses-García
The epithelial ovarian cancer (EOC) has been underdiagnosed because it does not have a specific clinical presentation, and the signs and symptoms are similar to the irritable bowel syndrome and pelvic inflammatory disease. EOC is less common than breast and cervical cancer, but it is more lethal. On the whole, EOC has an early dissemination to peritoneal cavity, which delays a timely diagnosis and increases the rate of advanced diagnosed disease. The diagnosis usually surprises the women and the primary care physician...
April 2016: Salud Pública de México
Suet-Yan Kwan, Xuanjin Cheng, Yvonne T M Tsang, Jong-Sun Choi, Suet-Ying Kwan, Daisy I Izaguirre, Hoi-Shan Kwan, David M Gershenson, Kwong-Kwok Wong
Inactivating mutations in ARID1A are found in a broad spectrum of cancer types, with the highest frequency in gynecologic cancers. However, therapeutic strategies targeting ARID1A-mutant cancer cells remain limited. In this study, we aimed to identify drugs sensitivities in ARID1A-mutant cancer cell lines. By analyzing the Genomics of Drug Sensitivity in Cancer database, we found that ARID1A-mutant cancer cell lines were more sensitive to treatment with the reactive oxygen species (ROS)-inducing agent elesclomol...
July 29, 2016: Oncotarget
Meng-Ti Hsieh, Le-Ming Wang, Chun A Changou, Yu-Tang Chin, Yu-Chen S H Yang, Hsuan-Yu Lai, Sheng-Yang Lee, Yung-Ning Yang, Jacqueline Whang-Peng, Leroy F Liu, Hung-Yun Lin, Shaker A Mousa, Paul J Davis
Ovarian cancer is the leading cause of death in gynecological diseases. Thyroid hormone promotes proliferation of ovarian cancer cells via cell surface receptor integrin αvβ3 that activates extracellular regulated kinase (ERK1/2). However, the mechanisms are still not fully understood. Thyroxine (T4) at a physiologic total hormone concentration (10-7 M) significantly increased proliferating cell nuclear antigen (PCNA) abundance in these cell lines, as did 3, 5, 3'-triiodo-L-thyronine (T3) at a supraphysiologic concentration...
July 21, 2016: Oncotarget
Chia-Lung Tsai, Angel Chao, Shih-Ming Jung, Chi-Neu Tsai, Chiao-Yun Lin, Shun-Hua Chen, Shih-Che Sue, Tzu-Hao Wang, Hsin-Shih Wang, Chyong-Huey Lai
Overexpression of stress-induced phosphoprotein 1 (STIP1) - a co-chaperone of heat shock protein (HSP) 70/HSP90 - and activation of the JAK2-STAT3 pathway occur in several tumors. Combined treatment with a HSP90 inhibitor and a JAK2 inhibitor exert synergistic anti-cancer effects. Here, we show that STIP1 stabilizes JAK2 protein in ovarian and endometrial cancer cells. Knock-down of endogenous STIP1 decreased JAK2 and phospho-STAT3 protein levels. The N-terminal fragment of STIP1 interacts with the N-terminus of JAK2, whereas the C-terminal DP2 domain of STIP1 mediates the interaction with HSP90 and STAT3...
July 8, 2016: Oncotarget
X-J Liang, J Shen
OBJECTIVE: Inhibition of angiogenesis has been regarded as an attractive treatment strategy for advanced or recurrent ovarian cancer. We conduct this meta-analysis to investigate the risk of adverse events of special interest related to angiogenesis inhibitors (AIs) in ovarian cancer. PATIENTS AND METHODS: Databases from PubMed, Web of Science and Cochrane library up to December 2015 were searched to identify relevant studies. Eligible studies included prospective randomized controlled phase II/III clinical trials evaluating therapy with or without AIs for ovarian cancer...
June 2016: European Review for Medical and Pharmacological Sciences
Wa Zhang, Carter J Barger, Kevin H Eng, David Klinkebiel, Petra A Link, Angela Omilian, Wiam Bshara, Kunle Odunsi, Adam R Karpf
PRAME is a cancer-testis antigen (CTA) and potential immuno-therapeutic target, but has not been well-studied in epithelial ovarian cancer (EOC) or its high grade serous (HGSC) subtype. Compared to normal ovary, PRAME expression was significantly increased most EOC, regardless of stage and grade. Interestingly, PRAME mRNA expression was associated with improved survival in the HGSC subtype. The PRAME locus was a frequent target for copy number alterations (CNA) in HGSC but most changes were heterozygous losses, indicating that elevated PRAME expression is not typically due to CNA...
June 13, 2016: Oncotarget
L Q Wang, W D Zhao, X J Jiao, D L Du, Y S Liu
UNLABELLED: Summary PURPOSE: Ovarian cancer is the most deadly of all gynecologic malignancies, due in part to the diagnosis at an advanced stage caused by the deficiency of specific marks and symptoms, by the absence of reliable tests for screening, and by early detection. MATERIALS AND METHODS: Insulin-like growth factor-I (IGF-I) is known to be involved in the development and promotion of diverse examples of solid tumors including ovarian cancer...
2016: European Journal of Gynaecological Oncology
J Krzystyniak, L Ceppi, D S Dizon, M J Birrer
BACKGROUND: Epithelial ovarian cancer (EOC) remains one of the leading causes of cancer-related deaths among women worldwide, despite gains in diagnostics and treatments made over the last three decades. Existing markers of ovarian cancer possess very limited clinical relevance highlighting the emerging need for identification of novel prognostic biomarkers as well as better predictive factors that might allow the stratification of patients who could benefit from a more targeted approach...
April 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
I A Khan, B H Yoo, O Masson, S Baron, D Corkery, G Dellaire, L D Attardi, K V Rosen
The ability of breast cancer cells to resist anoikis, apoptosis caused by detachment of the non-malignant epithelial cells from the extracellular matrix (ECM), is thought to be critical for breast tumor growth, invasion and metastasis. ErbB2, an oncoprotein that is often overproduced in breast tumors, can block breast cancer cell anoikis via mechanisms that are understood only in part. In an effort to understand them better we found that detachment of the non-malignant human breast epithelial cells from the ECM upregulates a protein Perp in these cells...
April 25, 2016: Oncogene
Monika Haemmerle, Justin Bottsford-Miller, Sunila Pradeep, Morgan L Taylor, Hyun-Jin Choi, Jean M Hansen, Heather J Dalton, Rebecca L Stone, Min Soon Cho, Alpa M Nick, Archana S Nagaraja, Tony Gutschner, Kshipra M Gharpure, Lingegowda S Mangala, Rajesha Rupaimoole, Hee Dong Han, Behrouz Zand, Guillermo N Armaiz-Pena, Sherry Y Wu, Chad V Pecot, Alan R Burns, Gabriel Lopez-Berestein, Vahid Afshar-Kharghan, Anil K Sood
Recent studies in patients with ovarian cancer suggest that tumor growth may be accelerated following cessation of antiangiogenesis therapy; however, the underlying mechanisms are not well understood. In this study, we aimed to compare the effects of therapy withdrawal to those of continuous treatment with various antiangiogenic agents. Cessation of therapy with pazopanib, bevacizumab, and the human and murine anti-VEGF antibody B20 was associated with substantial tumor growth in mouse models of ovarian cancer...
May 2, 2016: Journal of Clinical Investigation
Guoqing Cai, Xiangdong Ma, Biliang Chen, Yanhong Huang, Shujuan Liu, Hong Yang, Wei Zou
Paclitaxel resistance becomes common in patients with aggressive ovarian cancer and results in recurrence after conventional therapy. Galectin-3 is a multifunctional lectin associated with cell migration, cell proliferation, cell adhesion, and cell-cell interaction in tumor cells. Whether circulating galectin-3 is involved in paclitaxel resistance in ovarian cancer remains unknown. The current study investigated the effect of galectin-3 on toll-like receptor 4 (TLR4) signaling and thus paclitaxel resistance...
April 8, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Sherri L Stewart, Julie S Townsend, Mary C Puckett, Sun Hee Rim
Ovarian cancer is the deadliest gynecologic cancer. Receipt of treatment from a gynecologic oncologist is an evidence-based recommendation to reduce mortality from the disease. We examined knowledge and application of this evidence-based recommendation in primary care physicians as part of CDC gynecologic cancer awareness campaign efforts and discussed results in the context of CDC National Comprehensive Cancer Control Program (NCCCP). We analyzed primary care physician responses to questions about how often they refer patients diagnosed with ovarian cancer to gynecologic oncologists, and reasons for lack of referral...
March 2016: Journal of Women's Health
Antroula Papakonstantinou, Theodoros Foukakis, Kenny A Rodriguez-Wallberg, Jonas Bergh
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
May 10, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Niranjan Awasthi, Roderich E Schwarz
Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approved for cancer therapy. Novel antiangiogenic agents, such as sunitinib, sorafenib, pazopanib, or vandetanib that target additional proangiogenic signaling pathways beyond VEGF, have also been approved for the treatment of various malignant diseases...
2015: OncoTargets and Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"